A Phase 2 Study of ABSK043 Combined With Osimertinib
A Phase 2 Study of ABSK043 Combined With Osimertinib
Not yet recruiting · NCT07710612 · Registry updated 2026-07-17Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Phase 2 Study of ABSK043 Combined With Osimertinib | Non-Small Cell Lung Cancer With EGFR-mutated and PD-L1 Positive | Not yet recruiting | Phase 2 | 2026-07-17 | NCT07710612 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Abbisko Therapeutics Co, Ltd | 22 |
| AstraZeneca | 806 |
7 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Harbin Medical University Cancer Hospital | Harbin | China | 51 |
| Shanghai Chest Hospital | Shanghai | China | 31 |
| Shanxi Provincial Cancer Hospital | Taiyuan | China | 20 |
| The First Affiliated Hospital, Sun Yat-sen University | Guangzhou | China | 20 |
| The first affiliated hospital, Zhejiang university school of medicine | Hangzhou | China | 27 |
| The First Hospital of China Medical University | Shenyang | China | 43 |
| Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Wuhan | China | 77 |